BioSpace News Archive

NeoGenomics, Inc., a leading oncology testing services company, and ConcertAI, LLC, a leading oncology real-world evidence data and AI technology company, today announced a broad collaboration to advance large-scale hematological research solution to investigate real-world clinical practice and outcomes in hematological malignancies.

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2023.

Longboard Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its voting common stock, including 1,500,000 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares, at a price to the public of $21.00 per share.

MacroGenics, Inc. announced that the Company’s management will participate in the following upcoming investor conference:

Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary platform, announced the promotion of Samuel Deutsch, Ph.D., as the company’s chief scientific officer.

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that new data from the Phase III study that evaluated linaclotide in children and adolescents aged 6-17 years with functional constipation were published in The Lancet Gastroenterology & Hepatology.

Element Biosciences, Inc., developer of pioneering technologies to empower science, has received over 160 commercial orders of its AVITI benchtop sequencer and expanded its installed base to 112 instruments, the company announced at the J.P. Morgan 42nd Annual Healthcare Conference.

Asieris Pharmaceuticals has announced its set-up of the Women’s Health Business Unit for commercialization.

Evosep announced a co-marketing agreement with Thermo Fisher Scientific, a world leader in serving science.

European Commission Approves Pfizer’s TALZENNA ® in Combination with XTANDI ® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer.